MX9300294A - Metodo para inhibir al menos una porcion de una respuesta del anticuerpo especifico del antigeno mediante el sistema inmune de un mamifero - Google Patents
Metodo para inhibir al menos una porcion de una respuesta del anticuerpo especifico del antigeno mediante el sistema inmune de un mamiferoInfo
- Publication number
- MX9300294A MX9300294A MX9300294A MX9300294A MX9300294A MX 9300294 A MX9300294 A MX 9300294A MX 9300294 A MX9300294 A MX 9300294A MX 9300294 A MX9300294 A MX 9300294A MX 9300294 A MX9300294 A MX 9300294A
- Authority
- MX
- Mexico
- Prior art keywords
- mammal
- immune system
- specific antibody
- antibody response
- inhibiting
- Prior art date
Links
- 241000124008 Mammalia Species 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 230000008350 antigen-specific antibody response Effects 0.000 title abstract 2
- 210000000987 immune system Anatomy 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical class NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 abstract 2
- 102000000543 Histamine Receptors Human genes 0.000 abstract 1
- 108010002059 Histamine Receptors Proteins 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención proporciona métodos que usan derivados de histamina como inmunomoduladores en inmunoterapia. Más específicamente, la presente invención proporciona métodos para la inhibición de al menos una porción de una respuesta de anticuerpo específica de antígeno, por el sistema inmune de un mamífero, que comprende la administración a dicho mamífero de una cantidad efectiva de una composición que comprende al menos un derivado de histamina que tiene especificidad de enlace por lo menos un receptor de histamina.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82322992A | 1992-01-21 | 1992-01-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX9300294A true MX9300294A (es) | 1994-01-31 |
Family
ID=25238155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX9300294A MX9300294A (es) | 1992-01-21 | 1993-01-21 | Metodo para inhibir al menos una porcion de una respuesta del anticuerpo especifico del antigeno mediante el sistema inmune de un mamifero |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0621780A1 (es) |
| JP (1) | JPH07503239A (es) |
| CN (1) | CN1078153A (es) |
| AU (1) | AU3591793A (es) |
| CA (1) | CA2128331A1 (es) |
| MX (1) | MX9300294A (es) |
| WO (1) | WO1993013772A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090317357A1 (en) * | 2003-02-24 | 2009-12-24 | Lawrence Steinman | Methods for treating or preventing autoimmune disease using histamine h1 receptor-blocking agents |
| HRP20110348T1 (hr) | 2005-09-01 | 2011-07-31 | Celgene Corporation | Imunološke primjene imunomodulatornih spojeva za cjepivo i za liječenje infektivnih bolesti |
| JO3820B1 (ar) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
| EP3564671B1 (en) | 2013-08-23 | 2021-09-29 | Regeneron Pharmaceuticals, Inc. | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit) |
| EP3558347A1 (en) | 2016-12-22 | 2019-10-30 | Regeneron Pharmaceuticals, Inc. | Method of treating an allergy with allergen-specific monoclonal antibodies |
| WO2018138607A1 (en) * | 2017-01-24 | 2018-08-02 | Nestec Sa | Compositions comprising anti-fel d1 antibodies and methods for reducing at least one symptom of human allergy to cats |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4996221A (en) * | 1987-01-13 | 1991-02-26 | The Board Of Trustees Of The Leland Stanford Junior University | Histamine derivatives as immune modulators |
-
1993
- 1993-01-19 WO PCT/US1993/000664 patent/WO1993013772A1/en not_active Application Discontinuation
- 1993-01-19 AU AU35917/93A patent/AU3591793A/en not_active Abandoned
- 1993-01-19 CA CA002128331A patent/CA2128331A1/en not_active Abandoned
- 1993-01-19 JP JP5512737A patent/JPH07503239A/ja active Pending
- 1993-01-19 EP EP93904617A patent/EP0621780A1/en not_active Withdrawn
- 1993-01-21 CN CN93102512A patent/CN1078153A/zh active Pending
- 1993-01-21 MX MX9300294A patent/MX9300294A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1078153A (zh) | 1993-11-10 |
| CA2128331A1 (en) | 1993-07-22 |
| EP0621780A1 (en) | 1994-11-02 |
| AU3591793A (en) | 1993-08-03 |
| WO1993013772A1 (en) | 1993-07-22 |
| JPH07503239A (ja) | 1995-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX9300392A (es) | Derivados de histamina y metodo para usarlos como inmunomoduladores. | |
| AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
| CR20210326A (es) | Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor | |
| MX2020008184A (es) | Receptores de antigeno quimericos dirigidos a cd70. | |
| CO2019012143A2 (es) | Formulaciones estables de anticuerpos anti-ctla4 solos y en combinación con anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso | |
| WO2018023025A8 (en) | Combination therapies of chimeric antigen receptors and pd-1 inhibitors | |
| BR112022018949A2 (pt) | Anticorpos monoclonais humanos para síndrome respiratória aguda grave coronavírus 2 (sars-cov-2) | |
| PE20210115A1 (es) | Anticuerpos anti-tau y uso de los mismos | |
| BR112017018770A2 (pt) | redução da tolerância imunológica induzida por pd-l1 | |
| ATE513563T1 (de) | Therapeutische und toleranz-induzierende antikörper | |
| MX2017015811A (es) | Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4). | |
| BR112021024956A2 (pt) | Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3 | |
| DK0618813T3 (da) | Antigen for M-hybridprotein og bærer for gruppe A streptococcal vaccine | |
| BR0012196A (pt) | Método de tratamento de um tumor em mamìferos através do uso de conjugados de maitansinóide e anticorpo receptor anti-erbb e artigo industrializado | |
| MX9401225A (es) | Composicion de vacuna para prevenir la infeccion con influenza en humanos y metodo para su preparacion. | |
| MX2022000325A (es) | Anticuerpos dirigidos contra dll3 y usos de los mismos. | |
| PE20142170A1 (es) | Anticuerpos frente a los ligandos del receptor b1 de bradicinina | |
| ZA202206437B (en) | Claudin18.2 binding moieties and uses thereof | |
| PE20211708A1 (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anticgrp o anti-cgrp-r | |
| BR9809656A (pt) | Composição imunopotencializante | |
| HU9300538D0 (en) | Method for treating endotoxine shock by means of adhesion inhibiting antibodies | |
| DK0969873T3 (da) | Multiple carbonhydratholdige glycopeptid-antigener, vaccine indeholdende dem og anvendelse deraf | |
| ES2196150T3 (es) | Induccion de tolerancia inmunologica por el uso de anticuerpos anti-cd4 que no inducen deplecion. | |
| MX2022005816A (es) | Terapia de tumores solidos cd70+ utilizando linfocitos t genomodificados dirigidos a cd70. | |
| MX2022016039A (es) | Anticuerpos anti-cd2. |